Wyniki wyszukiwania - Biblioteka Nauki

Ten serwis zostanie wyłączony 2025-02-11.

Nowa wersja platformy, zawierająca wyłącznie zasoby pełnotekstowe, jest już dostępna.
Przejdź na https://bibliotekanauki.pl

Ograniczanie wyników

Znaleziono wyników: 6

Liczba wyników na stronie

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych: DRUG

Sortuj według:

Ogranicz wyniki do:

Aptamers RNA as potential antiviral drugs

100%

Tyczewska A. , Figlerowicz M. , Twardowski T.

2003

nr 2

153-164

SELEX is a method of the identification of high affinity aptamers for a surprising variety of molecular targets including nucleic acid binding proteins, non-nucleic acid binding proteins as well as small organic molecules. The aptamers against enzymes involved in infectious, malignant diseases are still being discovered by the process of SELEX. This procedure might be a way of finding new drugs that specifically and effectively block viral replication, e.g. HIV.

Animals as bioreactors ? the future of pharmaceutical industry?

80%

Tyczewska A. , Bakowska-Zywicka K.

Biotechnologia

2008

nr 3

64-70

Biotechnology products and its application raise many controversies. Discussions are carried out where the supporters of GMO are underlining the qualities of genetically modified organisms, and sceptics are pointing the dangers that, in their perspective, are exceeding the benefits. In this article, we intend to show the qualities resulting from the use of transgenic animals to produce cheaper drugs, as biotechnology and genetic engineering methods gave the possibility to use animals as bioreactors.

DRUG LAWS, ETHICS, AND HISTORY

80%

Greif A.

2019

tom 74

nr 2

95 – 110

In this paper, I present and criticize several historical arguments in favour of prohibition and criminalization of illicit psychoactive substances. I consider several versions of Charles Brent’s argument from drug harms and an argument from addiction based on Kantian view on autonomy. My criticism will mainly rely on empirical evidence on drugs, drug use, and addiction. I think that in light of this evidence, all of the arguments lose their cogency or can be refuted altogether. Moreover, the evidence reveals an inconsistency in the international drug law framework. Therefore, I provide in conclusion a general argument challenging the legitimacy of the existing distinction between licit and illicit drugs based on the inconsistency.

Pharmaceutical biotechnology: The achievements of Century XX and the expectations in Century XXI

80%

Chmiel A.

Biotechnologia

2002

nr 4

56-78

Pharmaceutical biotechnology is 60 years old. Its development one can divide into three essential periods. Two of them have proceeded in past century. The first period started during the Second Warld War with the industrial production of penicillin and was microbiology-based (microbial metabolites as drugs). The second one was genetic engineering-based and started in 1982, when human insulin synthesized in recombinant bacteria was introduced by pharmaceutical industry to health care. The third period began in 2001 with the first descriptions of the human genome, and is genome-based (also proteome-based). Molecular biology with its new areas genomics, farmacogenomics and proteomics, together with bioinformatics and other sophfisticated tools developed at the end of XX century and introduced (the pharmaceutical and medical biotechnology of the XXI century) very new ideas and new approaches to drug discovery and designin. Pharmaceutical biotechnology (as well as pharmaceutical industry as a whole and world biotechnology as a whole) is entering upon the third phase of its development, a very integrated and globalized one.

Peptide-based approaches to treat asthma, arthritis, other autoimmune diseases and pathologies of the central nervous system

70%

Hauff K. , Zamzow C. , Law W. J. , De_Melo J. , Kennedy K. , Los M.

Archivum Immunologiae et Therapiae Experimentalis

2005

tom 53

nr 4

308-320

In this review we focus on peptide- and peptidomimetic-based approaches that target autoimmune diseases and some pathologies of the central nervous system. Special attention is given to asthma, allergic rhinitis, osteoarthritis, and Alzheimer's disease, but other related pathologies are also reviewed, although to a lesser degree. Among others, drugs like Diacerhein and its active form Rhein, Pralnacasan, Anakinra (Kineret), Omalizumab, an anti-beta chain antibody 'BION-1', are described below as well as attempts to target beta-amyloid peptide aggregation. Parts of the review are also dedicated to targeting of pathologic conditions in the brain and in other tissues with peptides as well as methods to deliver larger molecules through the 'blood-brain barrier' by exploring receptor-mediated transport, or elsewhere in the body by using peptides as carriers through cellular membranes. In addition to highlighting current developments in the field, we also propose, for future drug targets, the components of the inflammasome protein complex, which is believed to initiate the activation of caspase-1 dependent signaling events, as well as other pathways that signal inflammation. Thus we discuss the possibility of targeting inflammasome components for negative or positive modulation of an inflammatory response.

Biopharmaceuticals- a basic tool of modern pharmacotherapy

60%

Kaliszan R. , Dlugokecka J.

2009

nr 5

33-49

Current status of innovative drug industry is briefly presented with emphasis on new biopharmaceuticals introduced in the years 1995-2007. Adverse effects and problems of safety and effectiveness of these pharmacotherapeutics are reviewed. A separate part of the manuscript is devoted to the newly introduced methods of molecular diagnostics based on pharmacogenomics and employed in personalized medicine. Theranostic approach consisting in a joint use of drugs and companion diagnostics are characterized.